VIVA and VEINS 2023: Late-Breaking Video Collection
Published: 27 November 2023
-
Views:
485
-
Likes:
7
-
Views:
485
-
Likes:
7
-
Up Next -
5m 10s -
10m 22sPart 1 | Session 4 Wearable Non-Invasive Ultrasound for CLTI -
10m 41sPart 1 | Session 5 STRIKE-PE: Indigo Aspiration System for PE -
6m 40sPart 1 | Session 6 PROMISE II: 12M Results From Pivotal Trial of LimFlow System
-
4m 2sPart 1 | Session 1 SAVER: Gender Subgroup Analysis Marianne Brodmann
Overview
Short, accessible Expert Interviews will be available with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
Part 1
Expert Interviews
About the episode
VEINS 23 - We are joined by Dr Mahmood Razavi (St. Joseph Heart & Vascular Center, US) to discuss the late-breaking findings of the VIVID trial, sponsored by Vesper Medical.
The VIVID Trial is a prospective, multicenter, single-arm, non-blinded clinical trial which aimed to investigate the efficacy and safety of the Vesper DUO Venous Stent System when compared to a pre-defined performance goal.
Safety results found that freedom from major adverse events was 98.7%, a statistically significant improvement over the performance goal. Efficacy results showed a patency rate of 90.2%, also a statistically significant finding.
Interview Questions:
- What was the reasoning behind this study?
- Could you tell us about the DUO Venous Stent System?
- What was the patient population and study design?
- What were the key findings?
- What are your take-home messages?
- What further study is needed, and what are the next steps?
Recorded remotely from Orange, 2023.
Comments